For U.S. Healthcare Professionals Only

Visit Sanofi U.S.:

 

 

Mucopolysaccharidoses are a group of rare, inherited lysosomal storage disorders caused by a deficiency of a lysosomal enzyme responsible for breaking down glycoaminoglycans or GAGs. The incidence of all MPSs disorders is approximately 1:50,000 to 1:25,000. The incidence of MPS I is approximately 1:100,000.

Each of the MPS disorders are listed below. The table outlines the associated genes and enzyme deficiencies in each of the MPS disorders.

To read more on disease presentation, please visit our Publication page here

 

mps disorders

 

 

The GAGs that accumulate in each of the MPS disorders varies. The table below highlights which GAGs are elevated in each of the MPS disorders.

 

glycosaminoglycan accumulation

Adopted from Zschocke/Hoffmann, Vademecum Metabolicum – Manual of Metabolic Paediatrics; 2nd Edition

 

Mucopolysaccharidosis I (MPS I)

Mucopolysaccharidosis Type I (MPS I) is one of the seven mucopolysaccharidoses. It is an inherited, multisystem, progressive disorder caused by a deficiency of the lysosomal enzyme α-L-iduronidase, which is encoded by the IDUA gene. Pathogenic mutations to the IDUA gene lead to a defective enzyme with lesser than normal alpha-L-iduronidase activity. The decreased activity of this enzyme causes GAGs, particularly dermatan and heparan sulfate, to accumulate in the lysosome. Over time the build-up of dermatan and heparan sulfate leads to excess cellular storage and cellular dysfunction which ultimately leads to cell death and organ-specific clinical manifestations. The tissues and organs which are affected varies.

References: 1. Arn P, et al. J Pediatr. 2009; 154:859-64 e3. 2. Clarke LA. NCBI Bookshelf, a service of the National Library of Medicine, National Institutes of Health (NIH). Available at: https://www.ncbi.nlm.nih.gov/books/NBK1162/. Accessed July 20, 2018.

 

 

gag accumulation

 

Systemic Effects of GAG Accumulation

The clinical severity of MPS I varies amongst patients and patients. MPS I patients are commonly categorized into one of three clinical groups depending upon their cognitive functioning. Patients with pronounced mental delays with loss of acquired skills are generally classified as Hurler or severe patients. Those with no to mild learning disabilities are commonly classified as Hurler-Scheie, and those with no cognitive impairments are classified as Scheie patients. Overall, all phenotypes across the MPS I spectrum are progressive and debilitating.

Multiple organ systems are affected in MPS I. The clinical presentation and organ involvement varies from patient to patient. Not all patients will experience the same symptoms. The figure below outlines some of the clinical presentations that can present in MPS I patients.

photo mpsisymptoms3

 



Muenzer J, et al. Pediatrics. 2009;123(1):19-29; Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic & Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001:3421-3452; Vijay S, Wraith JE.  Acta Paediatr. 2005;94(7):872-877; National MPS Society. A guide to understanding MPS I. http://mpssociety.org/wp-content/uploads/2011/07/booklet_MPS_I_v8.pdf. 2008.

 

 

Last Updated: Jan 24, 2020
What's New

What's New

Try our Pompe Patient Diagnosis Interactive to see if you can recognize Pompe Disease

Contact

Contact

Contact the Rare Diseases Medical Affairs team

Event Calendar

Event Calendar

Find Upcoming Events and Presentations on Our Event Calendar